Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Publication · Biomedical communication ethics

Principles and Ethics of Scientific Communication in Biomedicine: Obligations of Authors

Publication ethics is usually taught as a list of virtues, which may explain why it seldom changes behaviour. Expressed as obligations, it is concise and specific: authorship requires all four ICMJE criteria, the whole study must be reported including unsuccessful elements, funding and writing contributions must be disclosed, and each dataset should be published once. The evidence on how often these obligations are breached is more extensive than many researchers realise, and it indicates that authorship and duplication, rather than outright fraud, are the principal problems.

Pubrica AcademyWritten by the medical writing and biostatistics teams Reviewed byPubrica biostatistics team Published9 October 2026 Last checked9 October 2026 Reading time14 minutes Sources41 peer-reviewed

Most researchers encounter publication ethics as a declaration form at submission, long after the decisions it concerns have been made. The byline may have been determined by seniority months earlier, writing support arranged by a sponsor, and the dataset already presented in two conference abstracts and a regional journal. This article examines what the ICMJE, COPE and publication-practice guidelines require, what survey and retraction evidence indicates about where biomedical communication fails, and which of these decisions must be made before manuscript preparation begins.

Learning objectives

  • The four ICMJE authorship criteria, the requirement that all four be met, and the contribution of the fourth criterion
  • The distinctions between honorary authorship, ghost authorship and legitimate professional writing support
  • The evidence from retraction and survey data on the prevalence of misconduct, and its limitations
  • The elements that a sponsorship disclosure must address beyond a funding statement
  • The boundary between a secondary analysis and a redundant publication
  • The reasons incomplete reporting of a completed study is regarded as an ethical rather than an editorial failure

Common misconceptions

  • “The head of department always goes on the paper.” The ICMJE sets four authorship criteria and all four must be met. Departmental support, funding acquisition alone, or general supervision does not qualify anyone for a byline.
  • “Using a medical writer is ghostwriting.” It is not, provided that the writer is disclosed, the authors direct the work, and the authors themselves meet all four criteria. Ghostwriting consists in the failure to disclose, not in the use of assistance.
  • “Misconduct is mainly fabrication.” Fanelli’s meta-analysis in PLoS ONE found 1.97% of scientists admitting fabrication, falsification or data modification, against up to 33.7% admitting other questionable research practices. The most common problems are therefore not the most conspicuous ones.
  • “Retractions are mostly honest error.” Fang, Steen and Casadevall, in PNAS, found that of 2,047 retracted biomedical and life-science articles, 67.4% were retracted for misconduct and 21.3% for error.
  • “A null result is not worth publishing.” Antes and Chalmers argued in the Lancet that under-reporting of clinical trials is unethical, and the publication-bias evidence from Easterbrook and from Stern and Simes shows what the unreported subset does to the literature.

Publication ethics as obligations rather than virtues

When the aspirational language is removed from the ICMJE Recommendations, COPE’s Core Practices and the Good Publication Practice guidelines, four obligations remain. Each is specific enough to be breached in the course of ordinary work without any intention of wrongdoing.

Account for who did the work. The byline states who is responsible for the content, and it carries accountability as well as credit. Every listed author must satisfy the authorship criteria; every contributor who does not must be acknowledged, with the contribution named.

Report the study, not the findings you liked. The unit of ethical obligation is the study as designed, including a pre-specified outcome that proved disappointing and a trial that failed to recruit. Registration exists to make this verifiable.

Disclose what would change how the work is read. Funding, employment, the sponsor’s role in design and analysis, writing support, patents and advisory relationships should be disclosed. The test is not whether the author feels influenced but whether a reader would want to know.

Publish each dataset once. Secondary analyses and pre-specified sub-studies are legitimate and common; presenting the same results as new findings is not, and it is systematic reviewers whose work it damages.

Every other matter in this area is a special case of one of these four obligations. Rennie, Flanagin and Yank stated the first obligation most directly in JAMA when they argued for contributorship over authorship, and Davidoff and colleagues set out the third in Annals of Internal Medicine in the editors’ joint statement on sponsorship, authorship and accountability 36,37.

The four ICMJE authorship criteria

The ICMJE criteria require substantial contribution to conception or design, or to acquisition, analysis or interpretation of data; drafting the work or revising it critically for important intellectual content; final approval of the version to be published; and agreement to be accountable for all aspects of the work, including ensuring that questions about the accuracy or integrity of any part of it are appropriately investigated and resolved. All four must be met by each author. This point is the one most commonly overlooked: the criteria are conjunctive, not alternatives from which to choose.

The fourth criterion is the newest and the most consequential. The ICMJE describes the 2013 revision as the point at which a fourth criterion on accountability for the whole work was added, which changed authorship from a claim about contribution into a claim about responsibility 3. An author who contributed a dataset but cannot account for the analysis built on it does not satisfy this criterion. The consequence is uncomfortable in large collaborations, and it is intended.

The history of the document itself illustrates the importance of reading sources carefully. The ICMJE records that it was first published as the Uniform Requirements for Manuscripts Submitted to Biomedical Journals in 1978, while elsewhere it describes first publication in 1979, with major revisions in 1997, 2003 and 2010 before the 2013 renaming and restructuring 1,3. The discrepancy is trivial in itself but noteworthy: if the authoritative body’s account of its own dates is inconsistent, a second-hand summary of its requirements should not be relied upon. Authors should consult the Recommendations themselves before citing them.

Where authorship is contested, the practical course is to settle it at the protocol stage, in writing, against the four criteria, with a named decision-maker for disputes. The Pubrica note on when a statistician qualifies as an author examines the case that most often causes difficulty.

4ICMJE authorship criteria, all of which each author must meet
2013the revision that added the fourth criterion, on accountability for the whole work
1978first published, as the Uniform Requirements for Manuscripts Submitted to Biomedical Journals

Source: the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. The ICMJE’s own documents give 1978 in one place and 1979 in another for first publication, with major revisions in 1997, 2003 and 2010.

Honorary authorship, ghost authorship and legitimate writing support

Three distinct practices are described as ghostwriting and must be distinguished, because two of them are failures and the third is normal professional practice.

Honorary authorship is a name on the byline that does not meet the criteria, such as a department head, a grant holder, or a senior collaborator added for prestige or for political reasons. Ghost authorship is a substantial contributor, usually a professional writer or a sponsor’s employee, who is left off the paper and out of the acknowledgements. Disclosed professional writing support is neither: a writer who drafts under the authors’ direction, is named in the acknowledgements together with their funding source and employer, and does not claim authorship.

The prevalence evidence is specific. Wislar and colleagues, in the BMJ, surveyed six leading general medical journals and found that in 2008 the total prevalence of articles with inappropriate authorship was 21%, down from 29.1% in 1996 13. This represents a genuine improvement across a decade in which the criteria were widely publicised, yet it still means that roughly one article in five had an authorship problem 13. Gøtzsche and colleagues set out what should be done about ghostwriting in PLoS Medicine, and Ross and colleagues, in JAMA, used internal documents from the rofecoxib litigation to show guest authorship and ghostwriting operating as a system rather than as isolated lapses 21,22.

Legitimate writing support is governed by its own standards, which are specific. Jacobs and Wager set out the EMWA guidelines on the role of medical writers in Current Medical Research and Opinion; the AMWA position statement by Hamilton and Royer covers the same ground; the ISMPP position statement by Norris and colleagues adds the publication-professional perspective; and the Good Publication Practice guidelines, in the 2022 update by DeTora and colleagues in Annals of Internal Medicine and in the earlier GPP3 and GPP2 versions, set out how company-sponsored publications should be run 6,10,16,26,28,32. The common requirements are that authors direct the work and approve the content, that the writer is named with their employer and funder, and that no one is paid per publication or per outcome 6,28.

Whether writing support improves the paper is a separate question, on which the evidence is suggestive but not decisive. Gattrell and colleagues, in BMJ Open, and Mills and colleagues, in F1000Research, both reported associations between professional medical writing support and more complete reporting of randomised trials against established checklist items 7,8. Both studies are cross-sectional, so they cannot establish that the support caused the improvement rather than being commissioned by better-resourced teams. They provide a reason to disclose writing support with confidence rather than proof that it raises quality. The Pubrica medical writing page describes how Pubrica works within these rules.

Three practices described as ghostwriting, and the nature of each

SituationWhat is happeningStatusWhat to do instead
Honorary authorA name on the byline that does not meet all four ICMJE criteria, such as a department head, grant holder or senior collaborator added for prestigeA failure: credit without contribution, and accountability that no one can dischargeAcknowledge the support by name, state what it was, and keep them off the byline
Ghost authorA substantial contributor, often a professional writer or sponsor employee, absent from both byline and acknowledgementsA failure: the reader cannot see who shaped the textName them in the acknowledgements with employer and funding source, or on the byline if they meet all four criteria
Disclosed writing supportA writer drafts or edits under the authors’ direction, does not claim authorship, and is named with their employer and funderLegitimate, and governed by the EMWA, AMWA, ISMPP and Good Publication Practice guidelinesNo remedy is required, provided that the authors retain control of content and no payment is made per publication or per outcome
Qualifying contributor left offSomeone who does meet all four criteria is omitted, typically a junior researcher or a statisticianA failure, and the one least often discussedSettle authorship against the criteria at protocol stage, in writing, with a named arbiter

Categories as defined in the ICMJE Recommendations and COPE Core Practices, with professional writing standards from the EMWA guidelines (Jacobs and Wager), the AMWA position statement (Hamilton and Royer), the ISMPP position statement (Norris et al.) and Good Publication Practice (GPP 2022, GPP3, GPP2).

Sponsorship, conflicts of interest and data control

A funding statement is the least informative part of a disclosure. A reader needs to know who made which decisions, and the editors’ joint statement by Davidoff and colleagues in Annals of Internal Medicine made this explicit: authors should be able to state that they had access to the full dataset, that they controlled the decision to publish, and what role the sponsor played in design, conduct, analysis and reporting 36.

The high standard has a documentary rather than a theoretical basis. Hill and colleagues reviewed internal documents from the ADVANTAGE study in Annals of Internal Medicine and described a trial run substantially as a marketing exercise; Ross and colleagues, in JAMA, traced guest authorship and ghostwriting through the rofecoxib litigation record; and Angell, writing in JAMA, argued from these and similar cases that industry-sponsored clinical research had become a broken system 22,23,25. Rothman and colleagues, also in JAMA, proposed controls on professional medical associations’ relationships with industry on the same basis.

None of this constitutes an argument against industry-sponsored research, which produces most of the evidence underpinning licensed medicines. It is an argument for writing the sponsorship paragraph so that a sceptical reader can identify the decision rights. The paragraph should state the funder; state whether the funder participated in design, data collection, analysis, interpretation and the decision to submit; state who had access to the full dataset and who had final authority over the manuscript; and name any steering or publication committee and its members. Where a sponsor contractually held any of those rights, this should be stated rather than left for the reader to infer.

Complete reporting: registration, null results and reporting checklists

The obligation to report a completed study in full is the one most often treated as optional, yet it has the firmest ethical grounding of any obligation discussed here. Participants accepted risk and inconvenience to generate knowledge; withholding that knowledge because the results were unremarkable breaches the agreement with them. Antes and Chalmers made this argument in the Lancet, and the empirical case for taking it seriously comes from Easterbrook and colleagues, who documented publication bias in the Lancet, and from Stern and Simes, who showed in the BMJ that publication was systematically delayed for studies without statistically significant results 35,38,40.

Three mechanisms exist to make completeness verifiable, and all three are the author’s responsibility. The first is registration in a public registry, which the ICMJE requires at or before the time of first patient enrolment; Steinbrook set out the rationale in the New England Journal of Medicine, and retrospective registration at submission does not satisfy the policy 1,31. The second is pre-specification of the primary outcome, so that a reader can see whether what was reported is what the study set out to measure. The third is the reporting guideline for the study design: CONSORT 2010, from Schulz, Altman and Moher in Annals of Internal Medicine, for parallel-group randomised trials; STROBE, from von Elm and colleagues in the BMJ, for observational studies; PRISMA, from Moher and colleagues in PLoS Medicine, for systematic reviews 15,18,27. Our reporting guidelines hub maps each design to its checklist.

The checklist should be treated as a drafting aid rather than a submission formality. Every unmet item is information a reader cannot verify, which constitutes the ethical content of the requirement rather than its bureaucratic surface.

Redundant publication and its boundaries

Publishing the same results twice as though they were new findings inflates the apparent weight of evidence and distorts any meta-analysis that includes both copies. Angell and Relman identified the problem in the New England Journal of Medicine, Kassirer and Angell returned to it there as a reminder, and DeAngelis set out the editorial consequences in JAMA 30,39,41. The systematic-review damage was quantified by von Elm and colleagues in JAMA, who analysed articles used in systematic reviews and found several distinct patterns of duplicate publication, some of which are very difficult for a reviewer to detect because authorship and framing change between versions 29.

The boundary is narrower than authors may hope but wider than is often feared. Legitimate: a conference abstract followed by a full paper; a pre-specified secondary outcome paper; a long-term follow-up; a translation published with notice and the editors’ agreement; and a secondary analysis asking a genuinely different question of the same data. Not legitimate: the same primary analysis in two journals; division of one dataset into minimally different papers (salami slicing); re-presentation of results under a changed author list; and failure to inform an editor that related work is under consideration elsewhere.

The practical rule is disclosure rather than judgement. Authors should inform the editor in the cover letter of every related publication, submission and abstract, cite their own earlier work explicitly, and allow the editor to decide. An editor informed in advance rarely objects; an editor who discovers the overlap later acts under COPE’s Core Practices, and the outcome differs 4. Text recycling, the reuse of one’s own wording rather than one’s own results, is a separate and more contested matter, addressed in COPE’s text recycling guidelines, in Roig’s guide to ethical writing for the US Office of Research Integrity, and in the Pubrica page on what actually happens after plagiarism 2,9.

Inadequate and adequate byline and contribution statements

Almost all of this reaches the reader through two short passages: the author list and the statements that accompany it. The version below on the left is not a caricature; it closely resembles statements that Pubrica routinely receives, and each element reflects a decision made without any improper intention.

The statements around the byline

Nobody intended anything improper

All authors have read and approved the final manuscript. The authors thank Professor A, Head of Department, for his support and encouragement throughout the project, and the sponsor’s publications team for editorial assistance. This study was funded by the sponsor. The authors declare no conflicts of interest.

“Read and approved” covers one criterion of four. Nothing addresses contribution, critical revision or accountability for the whole work.

The writer is invisible. “Editorial assistance” from a sponsor’s publications team names no individual, employer or funder, which meets the definition of ghost authorship.

The department head is thanked ambiguously. A reader cannot determine whether he contributed, and if he is also on the byline, the problem is more serious.

“Funded by the sponsor” answers none of the questions that matter: who designed the study, who analysed it, who had access to the data, and who could decide to publish.

“No conflicts of interest” alongside sponsor funding is a combination that editors treat as a warning sign rather than a reassurance.

A reader can see who did what

JK and RS conceived and designed the study. RS, MB and PD recruited participants and collected the data. AT performed the statistical analysis and had full access to the complete dataset. JK and AT drafted the manuscript. All authors contributed to interpretation of the data, critically revised the manuscript for important intellectual content, approved the final version, and agree to be accountable for all aspects of the work, including the investigation and resolution of any question about the accuracy or integrity of any part of it. [Writer name], a professional medical writer employed by [agency] and funded by the sponsor, prepared the first outline and assisted with figure preparation and journal formatting under the direction of the authors; she did not participate in data analysis or interpretation and is not an author. The sponsor funded the study and was represented on the steering committee by MB, an employee of the sponsor; the academic investigators had unrestricted access to the full dataset and retained the right to publish independently of the sponsor. Professor A provided departmental support and is thanked above; he did not contribute to the work and is not an author. JK has received speaker fees from two companies in this therapeutic area, listed in the disclosure form; the remaining authors declare no competing interests.

Each author’s contribution is stated, and the accountability criterion is written out rather than assumed.

The writer is named with employer and funder, and her scope is defined, explicitly excluding analysis and interpretation.

The sponsor’s role is specified precisely: funding, a named employee on the steering committee, and the two decision rights of most concern to a reader.

Data access and publication independence are asserted by the authors, as the editors’ joint statement requires.

The non-contributing senior colleague is thanked and expressly excluded from authorship, which protects him as well as the record.

The disclosure is specific rather than a blanket denial.

The second version is longer but contains no information the team did not already possess; it records decisions that had been made without being stated. Each addition answers a question that a reader, an editor or, later, an investigator would otherwise have to ask, and two of them answer the questions Davidoff and colleagues identified in the editors’ joint statement on sponsorship, authorship and accountability. Authors most often resist the clause expressly excluding the department head from authorship, yet it most reliably prevents later disputes.

Prevalence of ethical failures and the limits of the evidence

The quantitative evidence is more favourable than researchers generally assume, and it does not support the common view that misconduct primarily means fabrication.

Fang, Steen and Casadevall analysed 2,047 retracted biomedical and life-science articles indexed in PubMed and found that 67.4% were retracted for misconduct (43.4% for fraud or suspected fraud, 14.2% for duplicate publication and 9.8% for plagiarism), against 21.3% for error 12. They also reported that the share of published articles retracted for fraud or suspected fraud had risen roughly tenfold since 1975, a rise not explained by growth in publication volume alone. Fanelli, in PLoS ONE, pooled survey data and found 1.97% of scientists admitting to having fabricated, falsified or modified data at least once, while up to 33.7% admitted other questionable research practices 17.

Interpreted carefully, these two datasets indicate something specific. Outright data fabrication is admitted by a small minority. The behaviours that a third of scientists admit to, such as selective reporting, convenient rounding, the exclusion of inconvenient observations and decorative citation, are those that distort the literature at scale, and most of them are failures of communication rather than of laboratory practice 17. When Wislar and colleagues’ finding of inappropriate authorship in 21% of articles across six leading journals in 2008 is added, the evidence describes a field in which the conspicuous offence is rare and the everyday one is common 13.

These figures cannot establish the true rate of any behaviour. Retractions measure detection and editorial willingness to act, not incidence, so a rising retraction rate is compatible with improving behaviour and better screening 12. Self-report surveys measure what respondents are willing to admit, which provides a lower bound rather than an estimate. Fanelli states this explicitly, and Titus, Wells and Rhoades, writing in Nature, argued from the same evidence that institutional handling, rather than individual conscience, is the decisive factor 17,24. Quoting these figures as prevalence estimates overstates what they show.

67.4%of 2,047 retracted articles were retracted for misconduct
43.4%for fraud or suspected fraud
14.2%for duplicate publication, and 9.8% for plagiarism
21.3%for error

Retracted biomedical and life-science articles indexed in PubMed as of 3 May 2012. Source: Fang FC, Steen RG, Casadevall A. Misconduct accounts for the majority of retracted scientific publications. Proceedings of the National Academy of Sciences of the USA.

Ethical responsibilities for press releases

The ethics of biomedical communication extend beyond the article. Woloshin and colleagues, in Annals of Internal Medicine, examined press releases issued by academic medical centres and found that they frequently promoted findings from weaker study designs without noting the limitations, and used language that implied more certainty than the underlying work supported 19. In most cases the releases were not written by the authors, which is precisely the problem: the claim that reaches the public is made by someone with no accountability under the authorship criteria.

The appropriate response is straightforward but seldom adopted. Authors should ask to review and approve any institutional or sponsor press release about their work before it is issued, and should check that the design is named, that the effect is given in absolute as well as relative terms, and that any conclusion about causation matches what the design can support. A sentence that would be inappropriate in the discussion section should not appear in a release bearing the institution’s name. The Pubrica pages on peer review and similarity screening cover the pre-publication checks; the post-publication claim is generally not checked at all.

Key points

Key points

Four obligations encompass almost all of publication ethics: accounting for who performed the work, reporting the study rather than selected findings, disclosing information that would alter how the work is interpreted, and publishing each dataset once. The ICMJE’s four authorship criteria are conjunctive, and the fourth, accountability for the whole work, added in the 2013 revision, is the criterion that disqualifies the honorary author. The evidence indicates that everyday failures are of greater consequence than conspicuous ones: Fanelli found 1.97% of scientists admitting data fabrication against up to 33.7% admitting other questionable practices, and Wislar and colleagues found inappropriate authorship in 21% of articles in six leading journals in 2008. Authorship, writing support and disclosure should be settled at the protocol stage, because by the time of submission they are established facts.

Application to your study

Application to your study

  1. Assess every name on the byline against all four ICMJE criteria, individually and in writing. A contributor who fails to meet any criterion should be listed in the acknowledgements with the contribution stated.
  2. Write the contribution statement in full sentences rather than as initials against a template. State who had access to the full dataset and who drafted the manuscript.
  3. Identify any writing support together with the writer’s employer and funder, and define its scope explicitly, including the elements the writer did and did not contribute to.
  4. Replace the funding statement with a statement of roles. Specify who designed the study, collected, analysed and interpreted the data, and decided to submit; who had data access; and who held final authority over the manuscript.
  5. List every related abstract, submission and publication in the cover letter and cite earlier related work in the text. An editor informed in advance rarely objects.
  6. Verify the registration date against the date of first enrolment before drafting the methods, because this is the one requirement for which no remedy exists.
  7. Use the reporting checklist for the study design as a drafting aid rather than a submission form, and treat each unmet item as information a reader cannot verify.
  8. Request approval of any press release concerning the work, and reject any sentence that would be inappropriate in the paper’s own discussion section.

Frequently asked questions

Yes; all four must be met by each author. They are: substantial contribution to conception or design, or to acquisition, analysis or interpretation of data; drafting the work or revising it critically for important intellectual content; final approval of the version to be published; and agreement to be accountable for all aspects of the work, including ensuring that questions about the accuracy or integrity of any part are investigated and resolved. The criteria are conjunctive rather than alternatives, which is what disqualifies the honorary author. The ICMJE describes the fourth criterion as having been added in the 2013 revision, which shifted authorship from a claim about contribution to a claim about responsibility.

Yes, provided three conditions hold: the authors direct the work and approve the content, the authors themselves meet all four ICMJE criteria, and the writer is named in the acknowledgements with their employer and funding source. What makes writing support unethical is concealment, not assistance. The standards are set out in the EMWA guidelines by Jacobs and Wager, the AMWA position statement, the ISMPP position statement and the Good Publication Practice guidelines, most recently the 2022 update in Annals of Internal Medicine. Gattrell and colleagues in BMJ Open and Mills and colleagues in F1000Research both found associations between professional writing support and more complete trial reporting, though both studies are cross-sectional and cannot show causation.

Sufficiently common that most researchers are likely to encounter it. Wislar and colleagues, in the BMJ, surveyed six leading general medical journals and found the total prevalence of articles with inappropriate authorship was 21% in 2008, down from 29.1% in 1996. The decline is genuine and occurred across a decade in which the ICMJE criteria were widely publicised, but roughly one article in five still had an authorship problem. The documentary record shows how systematic the practice can become: Ross and colleagues, in JAMA, traced guest authorship and ghostwriting through internal documents from the rofecoxib litigation, and Gøtzsche and colleagues set out proposed remedies in PLoS Medicine.

Legitimate: a conference abstract followed by the full paper; a pre-specified secondary outcome paper; long-term follow-up; a translation published with notice and editorial agreement; and a secondary analysis asking a genuinely different question. Not legitimate: the same primary analysis in two journals; division of one dataset into minimally different papers; re-presentation of results under a changed author list; and failure to inform an editor that related work is under consideration elsewhere. Von Elm and colleagues, in JAMA, found several distinct patterns of duplicate publication in articles used in systematic reviews, some very difficult for a reviewer to detect. The governing rule is disclosure: authors should inform the editor of all related work and allow the editor to decide.

The true rate is unknown, and the available figures measure something else. Fanelli, in PLoS ONE, pooled survey data and found 1.97% of scientists admitting fabrication, falsification or data modification, with up to 33.7% admitting other questionable research practices; as self-reports, these provide a lower bound rather than an estimate. Fang, Steen and Casadevall, in PNAS, found that 67.4% of 2,047 retracted articles were retracted for misconduct, with 43.4% for fraud or suspected fraud, against 21.3% for error, and that fraud retractions had risen roughly tenfold since 1975. Retractions measure detection and editorial action, not incidence.

More than the source of funding. The editors’ joint statement by Davidoff and colleagues in Annals of Internal Medicine asks authors to be able to state that they had access to the full dataset and controlled the decision to publish, and to describe the sponsor’s role. The paragraph should therefore name the funder; state whether the funder participated in design, data collection, analysis, interpretation and the decision to submit; state who had full data access and who held final authority over the manuscript; and name any steering or publication committee with its membership. Where a sponsor contractually held any of those rights, this should be stated. “Funded by X, no conflicts to declare” is the combination editors treat as a warning sign.

Yes, within the standard ethical framework. Antes and Chalmers argued in the Lancet that under-reporting of clinical trials is unethical, because participants accepted risk to produce knowledge that is then withheld, and because a literature assembled from favourable findings misleads clinicians. The evidence is substantial: Easterbrook and colleagues documented publication bias in the Lancet, and Stern and Simes showed in the BMJ that publication was systematically delayed for studies without statistically significant results. Prospective registration, which the ICMJE requires at or before first patient enrolment, exists to make the gap visible, which is why Steinbrook framed it in the New England Journal of Medicine as accountability rather than record-keeping.

Practically and ethically, yes, even where the author did not write it. Woloshin and colleagues, in Annals of Internal Medicine, examined press releases from academic medical centres and found that they frequently promoted findings from weaker designs without noting limitations and implied more certainty than the work supported. The claim that reaches the public is often made by someone with no accountability under the authorship criteria, which is precisely the gap. Authors should ask to review and approve any release before it is issued, and should check that the design is named, that effects appear in absolute as well as relative terms, and that causal language matches what the design can support.

References

  1. International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. ICMJE. 2026. read 9 October 2026. icmje.org
  2. Committee on Publication Ethics. Text recycling guidelines. COPE. 2013. read 9 October 2026. par.nsf.gov
  3. International Committee of Medical Journal Editors. The New ICMJE Recommendations (August 2013). ICMJE. 2013. read 9 October 2026. icmje.org
  4. Committee on Publication Ethics. Core Practices. COPE. read 9 October 2026. equator-network.org
  5. International Society for Medical Publication Professionals. GPP 2022: Good Publication Practice guidelines for company-sponsored biomedical research published in Annals of Internal Medicine (press release). ISMPP. 2022. read 9 October 2026. ismpp.org
  6. DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, Hanekamp E, Dormer L, DiBiasi F, Bridges D, Baltzer L, Citrome L. Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Annals of Internal Medicine. 2022;175(9):1298-1304. doi:10.7326/M22-1460 read 9 October 2026. doi.org/10.7326/M22-1460
  7. Mills I, Sheard C, Hays M, Douglas K, Winchester CC, Gattrell WT. Professional medical writing support and the reporting quality of randomized controlled trial abstracts among high-impact general medical journals. F1000Research. 2017;6:1489. doi:10.12688/f1000research.12268.2 read 9 October 2026. doi.org/10.12688/f1000research.12268.2
  8. Gattrell WT, Hopewell S, Young K, Farrow P, White R, Wager E, Winchester CC. Professional medical writing support and the quality of randomised controlled trial reporting: a cross-sectional study. BMJ Open. 2016;6(2):e010329. doi:10.1136/bmjopen-2015-010329 read 9 October 2026. doi.org/10.1136/bmjopen-2015-010329
  9. Roig M; US Office of Research Integrity. Avoiding plagiarism, self-plagiarism, and other questionable writing practices: a guide to ethical writing. US Office of Research Integrity. 2015. read 9 October 2026. equator-network.org
  10. Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, Citrome L, Gurr JA, Mooney LA, Moore BJ, Pena T, Sanes-Miller CH, Veitch K, Woolley KL, Yarker YE. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Annals of Internal Medicine. 2015;163(6):461-464. doi:10.7326/M15-0288 read 9 October 2026. doi.org/10.7326/M15-0288
  11. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191-2194. doi:10.1001/jama.2013.281053 read 9 October 2026. doi.org/10.1001/jama.2013.281053
  12. Fang FC, Steen RG, Casadevall A. Misconduct accounts for the majority of retracted scientific publications. Proceedings of the National Academy of Sciences of the USA. 2012;109(42):17028-17033. doi:10.1073/pnas.1212247109 read 9 October 2026. doi.org/10.1073/pnas.1212247109
  13. Wislar JS, Flanagin A, Fontanarosa PB, et al. Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey. BMJ. 2011;343:d6128. doi:10.1136/bmj.d6128 read 9 October 2026. doi.org/10.1136/bmj.d6128
  14. Das N, Panjabi M. Plagiarism: why is it such a big issue for medical writers? Perspectives in Clinical Research. 2011;2(2):67-71. doi:10.4103/2229-3485.80370 read 9 October 2026. doi.org/10.4103/2229-3485.80370
  15. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine. 2010;152:726-732. read 9 October 2026. care-statement.org
  16. Graf C, Battisti WP, Bridges D, Bruce-Winkler V, Conaty JM, Ellison JM, Field EA, Gurr JA, Marx M-E, Patel M, Sanes-Miller C, Yarker YE. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ. 2009;339:b4330. doi:10.1136/bmj.b4330 read 9 October 2026. doi.org/10.1136/bmj.b4330
  17. Fanelli D. How many scientists fabricate and falsify research? A systematic review and meta-analysis of survey data. PLoS ONE. 2009;4(5):e5738. doi:10.1371/journal.pone.0005738 read 9 October 2026. doi.org/10.1371/journal.pone.0005738
  18. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine. 2009;6:e1000097. read 9 October 2026. care-statement.org
  19. Woloshin S, Schwartz LM, Casella SL, Kennedy AT, Larson RJ. Press releases by academic medical centers: not so academic? Annals of Internal Medicine. 2009;150:613-618. read 9 October 2026. archive.emwa.org
  20. Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, et al. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA. 2009;301(13):1367-1372. read 9 October 2026. equator-network.org
  21. Gotzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, Gertel A, et al. What should be done to tackle ghostwriting in the medical literature? PLoS Medicine. 2009;6(2):e1000023. read 9 October 2026. archive.emwa.org
  22. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008;299:1800-1812. read 9 October 2026. archive.emwa.org
  23. Angell M. Industry-sponsored clinical research: a broken system. JAMA. 2008;300:1069-1071. read 9 October 2026. archive.emwa.org
  24. Titus SL, Wells JA, Rhoades LJ. Repairing research integrity. Nature. 2008;453:980-982. read 9 October 2026. archive.emwa.org
  25. Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Annals of Internal Medicine. 2008;149:251-258. read 9 October 2026. archive.emwa.org
  26. Norris R, Bowman A, Fagan JM, Gallagher ER, Geraci AB, Gertel A, et al. International Society for Medical Publication Professionals (ISMPP) position statement. Current Medical Research and Opinion. 2007;23:1837-1840. read 9 October 2026. archive.emwa.org
  27. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806-808. read 9 October 2026. care-statement.org
  28. Jacobs A, Wager E. EMWA guidelines on the role of medical writers in developing peer-reviewed publications. Current Medical Research and Opinion. 2005;21:317-321. read 9 October 2026. archive.emwa.org
  29. von Elm E, Poglia G, Walder B, Tramer MR. Different patterns of duplicate publication: an analysis of articles used in systematic reviews. JAMA. 2004;291(8):974-980. doi:10.1001/jama.291.8.974 read 9 October 2026. doi.org/10.1001/jama.291.8.974
  30. DeAngelis CD. Duplicate publication, multiple problems. JAMA. 2004;292:1745-1746. doi:10.1001/jama.292.14.1745 read 9 October 2026. doi.org/10.1001/jama.292.14.1745
  31. Steinbrook R. Public registration of clinical trials. New England Journal of Medicine. 2004;351:315-317. doi:10.1056/NEJMp048191 read 9 October 2026. doi.org/10.1056/NEJMp048191
  32. Hamilton CW, Royer MG; AMWA 2002 Task Force on the Contributions of Medical Writers to Scientific Publications. AMWA position statement on the contributions of medical writers to scientific publications. AMWA Journal. 2003;18:13-16. read 9 October 2026. archive.emwa.org
  33. Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies. Current Medical Research and Opinion. 2003;19(3):149-154. doi:10.1185/030079903125001767 read 9 October 2026. doi.org/10.1185/030079903125001767
  34. Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies: why we need another set of guidelines. Current Medical Research and Opinion. 2003;19(3):147-148. read 9 October 2026. ismpp.org
  35. Antes G, Chalmers I. Under-reporting of clinical trials is unethical. Lancet. 2003;361:978-979. read 9 October 2026. ismpp.org
  36. Davidoff F, DeAngelis CD, Drazen JM, Hoey J, Hojgaard L, Horton R, et al. Sponsorship, authorship, and accountability. Annals of Internal Medicine. 2001;135:463-466. read 9 October 2026. ismpp.org
  37. Rennie D, Flanagin A, Yank V. The contributions of authors. JAMA. 2000;284:89-91. read 9 October 2026. ismpp.org
  38. Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research papers. BMJ. 1997;315:640-645. read 9 October 2026. ismpp.org
  39. Kassirer JP, Angell M. Redundant publication: a reminder. New England Journal of Medicine. 1995;333:449-450. doi:10.1056/NEJM199508173330709 read 9 October 2026. doi.org/10.1056/NEJM199508173330709
  40. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867-872. read 9 October 2026. ismpp.org
  41. Angell M, Relman AS. Redundant publication. New England Journal of Medicine. 1989;320:1212-1214. doi:10.1056/NEJM198905043201812 read 9 October 2026. doi.org/10.1056/NEJM198905043201812

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 9). Principles and Ethics of Scientific Communication in Biomedicine: Obligations of Authors. Pubrica. https://pubrica.com/academy/medical-writing/what-are-the-principles-and-ethics-of-scientific-communication-in-biomedicine/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

Template pre-submission ethics statements

These four statements belong in every submission and are considerably easier to write while the study is recent than to reconstruct at revision. The bracketed fields should be completed and inapplicable elements deleted, and the sentence excluding non-contributors from authorship should be retained, because it prevents the most difficult disputes.

PUBLICATION ETHICS STATEMENTS
Manuscript: ______________________   Target journal: ______________________

1. AUTHORSHIP TEST  (complete for EVERY proposed author, before drafting)
   Name: ______________________
   [ ] Criterion 1: substantial contribution to conception or design, OR to
       acquisition, analysis or interpretation of data
       What exactly: ______________________________________________
   [ ] Criterion 2: drafted the work or critically revised it for important
       intellectual content
   [ ] Criterion 3: approved the version to be published
   [ ] Criterion 4: agrees to be accountable for ALL aspects of the work
   ALL FOUR met?  YES -> author   NO -> acknowledgement with contribution named

   Authorship order agreed on: __________  Arbiter if disputed: ____________

2. CONTRIBUTION STATEMENT  (write as sentences)
   Conceived and designed the study: ______________________
   Collected the data: ______________________
   Performed the analysis: ______________________
   Had access to the complete dataset: ______________________
   Drafted the manuscript: ______________________
   All authors contributed to interpretation, critically revised the manuscript,
   approved the final version, and agree to be accountable for all aspects of
   the work, including investigation and resolution of any question about the
   accuracy or integrity of any part of it.

3. WRITING SUPPORT  (include if ANY help was used)
   [Name], a professional medical writer employed by [employer] and funded by
   [funder], [what they did]. She/he did not participate in [excluded scope,
   e.g. data analysis or interpretation] and is not an author.

4. SPONSORSHIP AND ROLE STATEMENT
   Funder: ______________________
   Funder participated in:  design [Y/N]  data collection [Y/N]
                            analysis [Y/N]  interpretation [Y/N]
                            decision to submit [Y/N]
   Full dataset access held by: ______________________
   Final authority over the manuscript held by: ______________________
   Steering / publication committee and membership: ______________________
   Authors retained the right to publish independently:  YES / NO

5. PRIOR AND RELATED WORK  (list ALL in the cover letter)
   Conference abstracts: ______________________
   Related papers published: ______________________
   Related manuscripts under consideration elsewhere: ______________________
   Overlapping dataset previously reported in: ______________________
   [ ] Own earlier work cited explicitly in the text

6. COMPLETENESS
   Registry and ID: ______________________
   Registered on: __________   First enrolment: __________  (must be later)
   Primary outcome as pre-specified: ______________________
   Reporting guideline applied: ______________________
   [ ] Every checklist item addressed, or its absence explained

7. NON-AUTHOR CONTRIBUTORS  (acknowledge with the contribution named)
   Name / contribution: ______________________
   [ ] Statement included that named supporters who did not contribute to the
       work are not authors
   [ ] Written permission obtained from everyone named in acknowledgements

8. AFTER ACCEPTANCE
   [ ] Press release requested for author review before issue
   [ ] Design named in the release; absolute as well as relative effects given
   [ ] No causal claim the design cannot support

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica’s medical writing team operates within these rules: Pubrica is named together with its funder, does not contribute to analysis or interpretation unless commissioned and disclosed, and the authors direct and approve the content. For a given manuscript, Pubrica assesses each proposed author against all four ICMJE criteria, drafts the contribution, sponsorship and disclosure statements so that an editor need not request them, and identifies related abstracts or overlapping datasets that should be declared in the cover letter.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Pubrica can review a manuscript and author list and identify bylines and disclosures that may not withstand editorial scrutiny.

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.